← Back to Patent Explorer
US4123510A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for the determination of gonadotropins

Assignee: Wyeth LLC
•
Filing: 1977-06-14
•
Granted: 1978-10-31
•
Expires: 1997-06-14
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A simple, sensitive, reliable and safe method for determining the concentration of pituitary gonadotropins is disclosed. The method involves concentration by ultrafiltration of a sample of body fluid, e.g. urine or serum from a subject, followed by determining the presence of the gonadotropin in the concentrated sample.

Inventors

  • 👤 Upendra K. Banik
  • 👤 Morris L. Givner

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-01 23:09
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/74; G01N33/76; B; B01; B01D; B01D61/00; B01D61/14; B01D61/145; B01D63/00; Y; Y10; Y10S; Y10S436/00; Y10S436/811; Y10S436/814; Y10S436/815; Y10S436/817; Y10S436/818; Y10S436/825

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 200 words
A method suitable for detection of luteinizing hormone in urine at a concentration as low as about 25 m.I.U./ml of urine and capable of detecting ovulation in a cycling woman, which comprises: (a) clarifying a sample of the urine to be tested; (b) contacting the urine sample before, during or after clarification with 0.1 to 5% aqueous solution of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglobin, fibrinogen, human hemoglobin, and keyhold limpet hemomycin so that adsorption of luteinizing hormone from the sample onto the membrane is substantially reduced; (c) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane having a molecular weight cut-off from about 5,000 to about 50,000, whereby luteinizing hormone is retained in the sample; (d) continuing the ultrafiltration until the retentate sample is concentrated to one-tenth to one-five hundredth its original volume; (e) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and (f) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of luteinizing hormone in the retentate sample.
Claim 2
Independent Claim 200 words
A method suitable for detection of luteinizing hormone in urine at a concentration as low as about 25 m.I.U./ml of urine and capable of detecting ovulation in a cycling woman, which comprises: (a) clarifying a sample of the urine to be tested; (b) contacting the urine sample before, during or after clarification with 0.1 to 5% aqueous solution of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglobin, fibrinogen, human hemoglobin, and keyhold limpet hemomycin so that adsorption of luteinizing hormone from the sample onto the membrane is substantially reduced; (c) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane having a molecular weight cut-off from about 5,000 to about 50,000, whereby luteinizing hormone is retained in the sample; (d) continuing the ultrafiltration until the retentate sample is concentrated to one-tenth to one-five hundredth its original volume; (e) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and (f) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of luteinizing hormone in the retentate sample.
Claim 3
Dependent Claim 29 words
The method of claim 1 in which the luteinizing hormone is detected by a luteinizing hormone antiserum or a human chorionic gonadotropin antiserum which cross reacts with luteinizing hormone.
Claim 4
Independent Claim 199 words
A method for detecting follicle stimulating hormone or human menopausal gonadotropin in urine at a concentration of 15 or more m.I.U./ml of urine, which comprises: (a) clarifying a sample of the urine to be tested; (b) contacting the urine sample before, during or after clarification with 0.1 to 5% aqueous solution of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglobin, fibrinogen, human hemoglobin, and keyhold limpet hemomycin so that adsorption of follicle-stimulating hormone or human menopausal gonadotropin from the sample onto the membrane is substantially reduced; (c) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane having a molecular weight cut-off from about 5,000 to about 50,000, whereby follicle-stimulating hormone or human menopausal gonadotropin is retained in the sample; (d) continuing the ultrafiltration until the retentate sample is one-tenth to one-five hundredth its original volume; (e) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and (f) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of follicle-stimulating hormone or human menopausal gonadotropin.
Claim 5
Independent Claim 199 words
A method for detecting follicle stimulating hormone or human menopausal gonadotropin in urine at a concentration of 15 or more m.I.U./ml of urine, which comprises: (a) clarifying a sample of the urine to be tested; (b) contacting the urine sample before, during or after clarification with 0.1 to 5% aqueous solution of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglobin, fibrinogen, human hemoglobin, and keyhold limpet hemomycin so that adsorption of follicle-stimulating hormone or human menopausal gonadotropin from the sample onto the membrane is substantially reduced; (c) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane having a molecular weight cut-off from about 5,000 to about 50,000, whereby follicle-stimulating hormone or human menopausal gonadotropin is retained in the sample; (d) continuing the ultrafiltration until the retentate sample is one-tenth to one-five hundredth its original volume; (e) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and (f) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of follicle-stimulating hormone or human menopausal gonadotropin.
Claim 6
Dependent Claim 188 words
A test method suitable for detection of pituitary gonadotropins in urine at a concentration as low as about 15 m.I.U./ml of urine which comprises: (a) clarifying a sample of the urine to be tested; (b) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane, said membrane having been prewashed with 0.1 to 5% aqueous solution of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglogin, fibrinogen, human hemoglobin, and keyhold limpet hemocyanin so that adsorption of the gonadotropin from the sample onto the membrane is substantially reduced, and said membrane having a molecular weight cut-off from about 5,000 to about 50,000 whereby the gonadotropin is retained in the sample; (c) continuing the ultrafiltration until the retentate sample is one-tenth to one-five hundredth its original volume; (d) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and (e) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of the gonadotropin in the retentate sample.
Claim 7
Dependent Claim 188 words
A test method suitable for detection of pituitary gonadotropins in urine at a concentration as low as about 15 m.I.U./ml of urine which comprises: (a) clarifying a sample of the urine to be tested; (b) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane, said membrane having been prewashed with 0.1 to 5% aqueous solution of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglogin, fibrinogen, human hemoglobin, and keyhold limpet hemocyanin so that adsorption of the gonadotropin from the sample onto the membrane is substantially reduced, and said membrane having a molecular weight cut-off from about 5,000 to about 50,000 whereby the gonadotropin is retained in the sample; (c) continuing the ultrafiltration until the retentate sample is one-tenth to one-five hundredth its original volume; (d) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and (e) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of the gonadotropin in the retentate sample.
Claim 8
Dependent Claim 29 words
The method of claim 4 wherein said ultrafiltration membrane is of the anisotropic type and in which the membrane has a molecular cut-off from about 10,000 to about 35,000.
Claim 9
Dependent Claim 27 words
The method of claim 4, wherein said ultrafiltration membrane is of the anisotropic type and the concentration of said solution of protein is from 0.1 to 1.0%.
Claim 10
Dependent Claim 28 words
The method of claim 4 wherein said clarifying step comprises filtration through a filter and which further comprises prewashing said filter with the aqueous solution of a protein.
Claim 11
Dependent Claim 202 words
A test method suitable for detection of pituitary gonadotropins in urine at a concentration as low as about 15 m.I.U./ml of urine which comprises: (a) clarifying a sample of the urine to be tested; (b) contacting the urine sample before or after clarification with a sufficient amount of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglobin, fibrinogen, human hemoglobin, and keyhold limpet hemocyanin to give a concentration of the protein in the urine of from 0.001 to 1.0% so that adsorption of the gonadotropin from the sample onto the membrane is substantially reduced; (c) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane having a molecular weight cut-off from about 5,000 to about 50,000 whereby the gonadotropin is retained in the sample; (d) continuing the ultrafiltration until the retentate sample is one-tenth to one-five hundredth its original volume; (e) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and (f) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of the gonadotropin in the retentate sample.
Claim 12
Dependent Claim 202 words
A test method suitable for detection of pituitary gonadotropins in urine at a concentration as low as about 15 m.I.U./ml of urine which comprises: (a) clarifying a sample of the urine to be tested; (b) contacting the urine sample before or after clarification with a sufficient amount of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglobin, fibrinogen, human hemoglobin, and keyhold limpet hemocyanin to give a concentration of the protein in the urine of from 0.001 to 1.0% so that adsorption of the gonadotropin from the sample onto the membrane is substantially reduced; (c) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane having a molecular weight cut-off from about 5,000 to about 50,000 whereby the gonadotropin is retained in the sample; (d) continuing the ultrafiltration until the retentate sample is one-tenth to one-five hundredth its original volume; (e) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and (f) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of the gonadotropin in the retentate sample.
Claim 13
Dependent Claim 26 words
The method of claim 8 wherein said membrane is of the anisotropic type, said membrane being backed by a layer of absorbent capable of sorbing urine.
Claim 14
Dependent Claim 19 words
The method of claim 9 wherein the concentration of said protein in the urine is from 0.01 to 1.0%.
Claim 15
Dependent Claim 189 words
A test method suitable for detection of pituitary gonadotropins in urine at a concentration as low as about 15 m.I.U./ml of urine, which comprises: (a) clarifying a sample of the urine to be tested through a filter, said filter having been pretreated with an 0.1 to 5.0% aqueous solution of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglobin, fibrinogen, human hemoglobin, and keyhold limpet hemocyanin so that adsorption of the gonadotropin from the sample onto the membrane is substantially reduced; (b) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane having a molecular weight cut-off from about 5,000 to about 50,000, whereby the gonadotropin is retained in the sample; (c) continuing the ultrafiltration until the retentate sample is one-tenth to one-five hundredth its original volume; (d) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and (e) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of the gonadotropin in the retentate sample.
Claim 16
Dependent Claim 189 words
A test method suitable for detection of pituitary gonadotropins in urine at a concentration as low as about 15 m.I.U./ml of urine, which comprises: (a) clarifying a sample of the urine to be tested through a filter, said filter having been pretreated with an 0.1 to 5.0% aqueous solution of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglobin, fibrinogen, human hemoglobin, and keyhold limpet hemocyanin so that adsorption of the gonadotropin from the sample onto the membrane is substantially reduced; (b) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane having a molecular weight cut-off from about 5,000 to about 50,000, whereby the gonadotropin is retained in the sample; (c) continuing the ultrafiltration until the retentate sample is one-tenth to one-five hundredth its original volume; (d) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and (e) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of the gonadotropin in the retentate sample.
Claim 17
Dependent Claim 39 words
The method of claim 11 in which said membrane is of the anisotropic type having a molecular weight cut-off from about 10,000 to about 35,000 and wherein the concentration of said solution of protein is from 0.1 to 1.0%.

References Cited (Backward Citations)

US3485751A Cited
US3488768A Cited
US3991174A Cited
US3817379A Cited
US4033723A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1981-10-30 1982-05-01 1982-10-31 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1985-10-30 1986-05-01 1986-10-31 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1989-10-30 1990-05-01 1990-10-31 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag